GFI1-Dependent Repression of SGPP1 Increases Multiple Myeloma Cell Survival

SIMPLE SUMMARY: New therapies have greatly improved the progression-free and overall survival for patients with “standard risk” multiple myeloma (MM). However, patients with “high risk” MM, in particular patients whose MM cells harbor non-functional p53, have very short survival times because of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrusca, Daniela N., Mulcrone, Patrick L., Macar, David A., Bishop, Ryan T., Berdyshev, Evgeny, Suvannasankha, Attaya, Anderson, Judith L., Sun, Quanhong, Auron, Philip E., Galson, Deborah L., Roodman, G. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833953/
https://www.ncbi.nlm.nih.gov/pubmed/35159039
http://dx.doi.org/10.3390/cancers14030772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833953/
https://www.ncbi.nlm.nih.gov/pubmed/35159039
http://dx.doi.org/10.3390/cancers14030772

Ejemplares similares